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Abstract 
This document provides a summary of the areas considered by a working party of the Royal College 
of Paediatrics and Child Health in relation to updated practical guidance on ethical issues in 
research involving children 
Background 
The British Paediatric Association, the forerunner of the Royal College of Paediatrics and Child 
Health (RCPCH), first published guidance in relation to research involving children in 1980 [1]. Prior 
to this time little clinical research involved children. The 1980 guidance initiated a sea change, 
stating “research involving children is important”, “should be supported and encouraged” and 
“research which involves a child and is of no benefit to that child (non-therapeutic research) is not 
necessarily either unethical or illegal”. Updated guidance was issued by the RCPCH in 2000 [2]. 
Both documents have been cited extensively.   
The need for updating  
There are now many sources of detailed information for researchers, and the purpose of this paper 
is not to duplicate this material. The principles that underpin previous guidance remain valid, but 
there have been changes in their interpretation, scope, and application. Since the last RCPCH 
guidance the National Institute for Health Research (NIHR) has transformed the UK research 
environment. Changes in European Union regulations have facilitated children’s research, including 
medicines studies [3, 4]. There have been significant changes in the UK regulation and governance 
of research, with the involvement of a number of agencies, most recently the Health Research 
Authority. [5] There is a greater focus on involving children and their parents more actively in the 
design, review and conduct of studies. The ways in which society views clinical research have also 
continued to evolve. The Declaration of Helsinki that sets out the ethical principles that underpin 
medical research involving all human subjects has had two notes of clarification and seven 
amendments, the most recent in 2013. [6] 
In recognition of these changes, a working party led by the RCPCH was established with 
representatives from the Royal College of Nursing, Ethics and the Law Advisory Committee of the 
RCPCH, National Research Ethics Service, Medicines & Healthcare Regulatory Agency, General 
Medical Council, Medical Research Council, WellChild, Medicines for Children Research Network 
(MCRN), NIHR Paediatrics (non-medicines) Speciality Group, and NIHR MCRN Young Person’s 
Advisory Group. The remit was to provide updated practical guidance on ethical issues in relation 
to research involving children. Here we provide a summary of the areas considered.  
Children’s rights and interests 
Children require protection, but this should not preclude the claim of other rights, including the 
right to the highest standard of health care, to be informed, express their views, and influence 
decisions made about them [7]. The view of the NIHR MCRN Young Persons Advisory Group is that 
children should be offered the opportunity to participate in research, and have their care “assured 
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by research”. The current version of the Declaration of Helsinki makes no specific provision for 
children [6], only including a stipulation that special consideration is required for research involving 
vulnerable populations. The biology of many diseases and the responses to treatments differ in 
children and adults, hence conclusions extrapolated from studies in adults often have limited 
relevance and may be harmful. Innovative or experimental treatments are not necessarily better 
than existing treatments [8] and without information from research there will be continuing 
uncertainties in the care that children receive. The RCPCH recognises the need to increase and 
strengthen children’s research. [9] The RCPCH supports the conduct of research in children that 
has the objectives of understanding, preventing and treating disease and preserving health. All 
clinical research must be reviewed and approved by a Research Ethics Committee.  
Research risk 
Every research study must be preceded by a careful assessment of predictable risks in comparison 
with possible benefits to the individual and the population affected by the condition. Measures to 
minimise risk include appropriate research design, delivery by personnel trained in the procedures 
to be used and experienced in caring for children, and methods to reduce the volumes of blood or 
tissue required. Blood sampling is often regarded as a concern in relation to the pain, and risk of 
research participation. However effective anaesthetic creams are now available and sampling from 
indwelling lines placed as part of clinical care is painless, but expert knowledge is required of the 
use of these medications and the volume of blood that it is safe to take. Risk should be quantified 
as objectively as possible and contextualised in relation to the child’s life (e.g. describing the dose 
of radiation in terms of years of exposure to natural background radiation), and if applicable, the 
child’s experience of the condition. The risk of the disease, treatments and clinically required 
procedures, should be clearly distinguished from the risk of the research.  
Research should ideally carry no greater than minimal or low risk [2]. However research that 
involves greater than minimal risk may be acceptable if the interventions involve diagnostic 
procedures or treatments that are important for the individual child, and are likely to provide 
information that will improve understanding or treatment of the condition. Many phase 1 
investigational medicinal product studies do not achieve regulatory approval because of concerns 
about safety and efficacy [10]. In general therefore medicines should be tested in adults first, with 
testing in children deferred until phase 3 trials. Exceptions are situations where the condition is life 
threatening and no alternative therapies exist, the condition is life limiting and all accepted 
therapies have failed, or where the condition has no adult analogy and the impact is significant.  
Researchers or regulators may categorise a study as ‘high risk’, whereas the family may consider a 
risk to be reasonable if the child or other children are likely to benefit. The RCPCH strongly 
recommends seeking the views of children affected by the condition and their parents, about the 
research and the risks they regard as acceptable and reasonable.  
Consent, assent and dissent  
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The voluntary consent of a research participant who has been provided with appropriate 
information, or the consent of a person legally authorised to act on their behalf, remains 
fundamental to the conduct of research. Formal consent must usually be obtained and 
documented before enrolment and should be re-affirmed, although not necessarily in writing, at 
each research encounter. This is especially relevant to those studies conducted over long periods in 
which the child’s legal status changes or where their capacity to understand information about the 
study matures. For children lacking capacity to provide appropriately informed consent for 
research, this must be obtained on their behalf from a parent, or legally authorised representative; 
the child’s active affirmative agreement (assent) should also be sought. By the age of seven, many 
children are able to give assent and lack of objection should not be construed as assent. In those 
with capacity, consent may be withdrawn at any time without reason and without penalty. 
The acquisition of capacity is a developmental continuum and children over 12-14 years of age may 
have near adult capacity. This poses potential difficulties in law. The legal test for capacity as it 
applies to medical treatment for those under 16 years of age, is the ability to understand what is 
involved and the consequences (so-called Gillick or Fraser competence) [11]. As there is no direct 
case or statute law in the UK covering non-clinical trial research, it has been presumed that the test 
of Gillick competence applies. In most instances the child’s assent or consent should be 
underpinned by parent consent, but this can be problematic where sensitive subjects such as 
sexual health, contraception, and adolescent behavioural studies are involved and there is a duty 
to preserve confidentiality. In such cases the need for parental assent or consent should be 
carefully considered [12].  
The Medicines for Human Use (Clinical Trials) Regulations 2004 are the current legal basis for 
consent in Clinical Trials of Investigational Medicinal Products that involve children [4], though 
likely to be superseded by new European Union regulations in the near future. Here, a minor is 
defined as a child of less than 16 years of age. A person with “Parental Responsibility” or a legally 
authorised representative is required to provide consent on behalf of a “minor,” even if s/he has 
evidential capacity, and the assent of the “minor” should also be sought. Consent must be 
obtained from those over 16 years, and from participants reaching the age of 16 during the course 
of a study.   
Dissent is refusal to grant, or subsequent withdrawal of consent or assent. Dissent is not 
necessarily legally determinative, other than for Clinical Trials of Investigational Medicinal 
Products, especially if it places a child at risk of significant harm. However In the context of 
research dissent should be respected, even if parent consent continues.  
Research involving pregnant women  
Research involving enrolment during pregnancy may require the involvement of the newborn baby 
in the research protocol. There is an explicit legal requirement for a person with “Parental 
Responsibility” [13] to provide consent on the behalf of a newborn baby, but lack of clarity in 
current guidance as to whether antenatal enrolment of a mother should be followed by additional 
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formal written agreement for her baby to participate in any postnatal component of the study. In 
many circumstances the involvement of the baby may involve no more than the use of routinely 
collected clinical data, or a simple procedure such as obtaining the baby’s weight or length, or 
sample of urine from the nappy. Alternatively it may involve a non-trivial procedure, such as a 
scan, blood sample, or additional out-patient attendance. The principle to be followed is that of 
consent as a continuing process as discussed above. The mother should have opportunity to 
discuss the study again with the researcher, and her on-going agreement obtained for the 
participation of her baby if there are further active interventions. It is recommended that there 
should be formal documentation if the baby is to be involved in more than non-trivial procedures. 
Whether her on-going agreement for her baby to be involved will be documented in writing should 
be made explicit in the research protocol and the Research Ethics Committee approved 
information sheets.  
Research in pregnancy may involve “minors” (mothers less than 16 years of age). Here practice in 
relation to consent should be based on the competence of the mother to understand the issues 
involved (Gillick/Fraser competence) [11]. The researchers should consider whether the consent or 
assent of the mother’s mother or father, or other legal representative, is also necessary. 
Researchers aiming to recruit pregnant women may find it helpful to discuss these issues with 
experienced researchers and relevant parent groups at the planning stage.   
Research in urgent or emergency situations  
Research is needed to improve care in urgent and emergency situations but should only be 
undertaken in these situations if absolutely necessary and if non-emergency research will not 
resolve the uncertainties. The Mental Capacity Act [14] makes provision for research in 
incapacitated adults in emergency situations. It can be argued that similar considerations apply in 
this situation in children, and criteria that justify proceeding without initial informed consent have 
been developed [15]. Children are particularly vulnerable to being excluded because of the 
difficulty in obtaining appropriately informed consent under these circumstances [16]. The child, 
even if normally competent to make decisions, will be unable to do so, and parents, even if 
present, may find themselves in a position of “situational incapacity” where their capacity is 
compromised by the extreme stress of the situation, the time-critical nature of the intervention, or 
their own condition, such as a mother after delivery under general anaesthesia. If enrolment were 
only possible with parental consent this would preclude the participation of many infants and 
children in emergency research. This is clearly undesirable and hence the concept of “deferred 
consent” has arisen [17]. Here enrolment in emergency situations without parental consent is 
acceptable, if followed by explanation and information as soon as possible afterwards when formal 
written consent for ongoing involvement is sought, and that it is made clear that refusal for 
continued participation or withdrawal can take place at any time. Deferred consent is based upon 
the ethical principles of standard informed consent with the difference that the process is split 
temporally. Recent research has emphasised that parents are not necessarily averse to considering 
research participation for their children in such circumstances [18, 19]. However if no parent is 
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available, the concept of “substituted acceptance” might apply. Here someone else is consulted to 
confirm eligibility and provide consent as a “legal representative”. This may be the doctor primarily 
responsible for child’s treatment if she or he is not involved in study as a researcher. Consideration 
should be given to providing general information in advance if appropriate (e.g. information about 
newborn resuscitation research could be provided in antenatal clinics or at booking). In all cases 
the parent/carer should be provided with good information at the right time and is then able to 
decide whether or not to give consent for on-going involvement. 
For Clinical Trials of Investigational Medicinal Products there was no exception formerly for 
emergencies and consent had to be given on behalf of a minor before recruitment by a person with 
parental responsibility or a legal representative. [4] The Medicines for Human Use (Clinical Trials) 
and Blood Safety and Quality (Amendment) Regulations that came into force 2008 allows minors to 
be entered into a trial prior to informed consent being obtained provided that urgent action is 
necessary, it is not practicable to obtain informed consent prior to enrolment, and the intervention 
is approved by a Research Ethics Committee. [20] 
Research with particularly vulnerable children 
Children with life-threatening illnesses, looked-after children, their families, and bereaved families 
require a robust evidence base for both physical and psychosocial aspects of care. However 
evidence remains limited and largely focussed on aspects such as symptom relief. The fear of 
intruding on children that are especially vulnerable, and their families, and the perceived need to 
provide them with extra protection has led to reluctance to involve them in research [21]. However 
there is now considerable evidence that families and young people who participate in research find 
it beneficial rather than harmful [22], with opportunity to speak about illness and death, express 
painful emotions, and obtain release from isolation [23-26]. There is also evidence of a 
‘maturational effect’ of life ending illnesses where children and young people express a wish to 
benefit others, and benefit themselves from such “meaningful” encounters [27].  Research in these 
sensitive areas, including qualitative studies, requires review by Research Ethics Committees that 
have the necessary knowledge, and expertise.  
Sedation for research procedures 
Sedating active infants and children may be essential for some procedures such as certain forms of 
respiratory function testing which of themselves are of minimal risk [28]. Oral sedation in healthy 
infants and children carries minimal additional risk and is usually associated with no more than 
occasional vomiting or short-lived disturbance of sleep. Children born preterm and other at-risk 
groups such as those with respiratory problems or other co-morbidities may require short-stay 
observation facilities as they are at greatest risk of adverse effects from sedation) [29-31]. General 
anaesthesia for research purposes is normally unacceptable except where the potential benefit 
outweighs the risks (e.g. where a tissue biopsy, imaging study or other investigation is required to 
assign treatment in a clinical trial of a life-threatening or progressive illness). Researchers must 
justify the use of sedation, and provide evidence that appropriate monitoring will be in place 
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during the procedure, and that they possess the necessary competences and skills to carry out the 
procedures and to deal immediately with any adverse effects. The protocol must demonstrate the 
importance of the study, and evidence of a rigorous risk benefit analysis.  
Unexpected findings detected during research investigations  
With increasing use of new technologies unexpected findings may emerge in the course of a 
research study, for example from a blood test, imaging, or other investigation. The spectrum of 
possible findings will have varying implications, treatability and severity. Researchers have a moral 
responsibility and clinician researchers may have a “duty of care” towards research participants. 
Before carrying out the investigation investigators should consider how to address such findings 
and, if appropriate, explain the possibility of an unexpected finding, the course of action should 
this occur, such as arranging for the involvement of a senior paediatrician or the participant’s 
General Practitioner, or taking no action. This process should be made explicit in the study 
protocol, and in the Participant Information Sheet. The Medical Research Council/Wellcome Trust 
will shortly be issuing guidance that will include a framework to help investigators decide on the 
best approach.  
Commercial sponsorship, payment of researchers, and conflicts of interest 
Commercial sponsorship and partnership provides an important source of research development, 
support and funding and is a major component of UK government strategy for biosciences. 
Sponsorship from companies whose products are harmful to children, such as tobacco, alcohol or 
armaments, is in the view of the RCPCH, unacceptable.  A controversial area for the RCPCH and its 
members and fellows is sponsorship from the manufacturers of breast milk substitutes [32]. A 
working party of the RCPCH [33] considered these issues carefully and concluded “Collaboration 
with commercial companies is important for the care of children and their families. For example it is 
necessary that paediatricians should collaborate fully with research to produce drugs and other 
products, such as breast milk substitutes to the highest scientific standards. The College should 
support this process and be legitimately involved in it.” This report and recommendations were 
accepted by RCPCH Council and remain valid to this time. 
Sources of research funding and potential conflicts of interest should be declared and transparent. 
In England the Health Research Authority through the National Research Ethics Service has 
responsibility for ensuring that research ethics review is independent of sponsors, funders, and 
academic institutions. All sponsorship arrangements should be transparent, accountable and 
subject to appropriate scrutiny. Clinical trials must be registered, the results published or 
otherwise made available, and the data disclosed within a reasonable timescale, if requested.  
Financial incentives for recruitment may exert undue influence on researchers and compromise 
the scientific validity of a study. Financial incentives for recruiting or referring children are 
unacceptable. Advertisements may be helpful for recruitment and are acceptable provided that 
they present a truthful, balanced account of risks and potential benefits, and receive Research 
Ethics Committee approval.  
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Payments for participation of children in research 
A “reimbursement” is payment of expenses incurred through involvement in a research study. 
“Compensation payments” additionally reward participants for the time and effort of involvement 
in the study. “Appreciation payments” are small tokens given after study completion. “Incentive 
payments” are designed to encourage enrolment through promise of financial gain.  
Reimbursement of costs incurred through research participation, such as travel costs, is 
appropriate. Compensation for time spent in research participation is often offered in adult studies 
but controversial in children’s studies because of the concern that they may undermine the 
voluntariness of consent, exploit weak and vulnerable subjects and create selection bias [34]. 
However evidence that they have these consequences or that they increase risk-taking behaviours 
is limited. The situation is further complicated in countries in which sections of the population have 
limited access to healthcare on financial grounds and where research may provide ‘free access’ to 
a treatment they might otherwise not be able to receive.  
Guidance over payments in clinical trials or other research is complex and inconsistent. The EU 
Clinical Trials directive prohibits incentives or financial inducements but does permit 
“compensation” without further specification [3]. The Medicines for Human Use (Clinical Trials) 
Regulations 2004 has the same prohibition for children and their families, but appears to specify 
that compensation applies in the event of injury or loss [4].  
The UK NIHR Medicines for Children Research Network has investigated young people’s views on 
whether or not the offer of an appreciation payment would influence their decision to take part. 
Their view was that participation in simple, quick and non-invasive studies should be altruistic and 
payment would not be expected. For invasive clinical studies they expressed strong concern that 
any payment other than reimbursements and tokens of appreciation would be an inducement, and 
hence unacceptable. The nature of any token of thanks should be in proportion with the age of the 
child, approved by the Research Ethics Committee, and made clear in the Parent/Patient 
information sheets. 
Student research  
Research undertaken by undergraduate or postgraduate students, and trainees, can provide 
valuable educational opportunities, but poor research serves neither student nor participant well. 
Students cannot be expected to undertake major research projects nor is it justifiable to recruit 
participants to a study that will not produce meaningful results. However when well integrated 
into the activities of a large research group, student research can provide valuable contributions to 
wider goals and patient benefit, for example through acquiring pilot or feasibility data, assisting a 
qualified researcher with measurements, consulting user groups, and conducting systematic 
reviews or meta-analyses that are an essential prelude to the design of adequately powered high 
quality clinical trials. It is the supervisor’s responsibility to ensure that extravagant claims about the 
research are avoided, and that there is clarity about the reasons for the project (e.g. how a small, 
preliminary, or pilot study carried out by a student fits into a wider research strategy to benefit 
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patients or improve knowledge or understanding). This information and the review and approvals 
process that the research has received, must be made clear to participants and parents. The 
supervisor should attend with the student to present the study to the Research Ethics Committee. 
Researcher competencies 
It is recommended that anyone involved in clinical research receives training in Good Clinical 
Practice, the standard to which research should be conducted [35] as laid down in the Research 
Governance Framework for Health and Social Care 2005 that covers research in the National 
Health Service in England. [36] Researchers working with children must be appropriately qualified 
by education, training and experience and able to demonstrate that they have the necessary 
competencies. These include an understanding of physiology, growth and development, the 
pharmacological properties and side effects of any medicines involved, and the methodological, 
ethical and legal principles underpinning the study. They must be proficient in the techniques 
required, possess the necessary skill and knowledge to seek informed voluntary consent from 
participants and their parents, demonstrate professional integrity, openness and transparency in 
presenting relevant conflicts of interest, and maintain complete and honest research records. It is 
the responsibility of researchers to ensure that they understand the regulatory framework that 
governs the conduct of any study to which they contribute.  
Research involving UK paediatricians conducted in other countries  
Researchers based in the UK may lead or be involved in research in other countries. Research 
regulatory frameworks differ from country to country. The Nuffield Council of Bioethics provides 
guidance on research in developing countries, recommending that in addition to evaluation of 
scientific validity, and ethical acceptability, the relevance of the study to the healthcare priorities 
of the country where it is being conducted should be considered [37]. UK Research Ethics 
Committees are able to provide a view without delivering a formal opinion, and researchers might 
find it useful to consult a committee experienced in children’s research for advice. In addition to 
meeting local requirements where these exist, UK paediatricians should conduct research in 
accordance with UK ethical principles and the Declaration of Helsinki, placing the wellbeing of the 
child foremost. 
Concluding remarks  
The ethical principles underpinning the participation of children in clinical research have evolved 
over the last decades, and will continue to evolve. Recent positive developments are greater 
involvement of young people and parents in all aspects of research, and appreciation that 
regulation, while providing protection for participants and researchers alike, and consistency of 
processes, is also crucial to benefit health and wellbeing through facilitation of high quality 
research. Efforts to reduce uncertainties in care through carefully conducted, methodologically 
rigorous, closely regulated, ethical research is an imperative that every clinician should uphold. 
Confidence in conduct to the highest ethical standards will help move clinical research from the 
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exception to the norm, a necessary pre-requisite to improve children’s life-long health, and further 
understanding and treatment of common illnesses and rare diseases. 
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